Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of “Hold” from Analysts

Pulmonx Corporation (NASDAQ:LUNG) has been given an average rating of “Hold” by the ten analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $6.8071.

LUNG has been the topic of several recent analyst reports. Lake Street Capital lowered their target price on shares of Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, October 28th. D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of Pulmonx in a report on Thursday, November 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pulmonx in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th.

Pulmonx Stock Performance

Shares of NASDAQ LUNG opened at $1.47 on Monday. The company has a market capitalization of $60.64 million, a PE ratio of -1.04 and a beta of 0.07. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.15 and a current ratio of 4.86. The company’s fifty day moving average price is $2.01 and its 200 day moving average price is $1.80. Pulmonx has a 1 year low of $1.31 and a 1 year high of $9.37.

Institutional Trading of Pulmonx

A number of institutional investors and hedge funds have recently modified their holdings of LUNG. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Pulmonx by 32.1% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 218,758 shares of the company’s stock valued at $567,000 after buying an additional 53,148 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund acquired a new stake in Pulmonx during the second quarter worth $197,000. R Squared Ltd purchased a new stake in Pulmonx in the second quarter valued at $41,000. FNY Investment Advisers LLC purchased a new stake in Pulmonx in the third quarter valued at $29,000. Finally, Jain Global LLC acquired a new position in shares of Pulmonx in the 3rd quarter valued at $30,000. Hedge funds and other institutional investors own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.